Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system

Archives of Internal Medicine

Volumn 172, Issue 20, 2012, Pages 1582-1589

  Toh, Sengwee ^a   Reichman, Marsha E ^b   Houstoun, Monika ^b   Southworth, Mary Ross ^b   Ding, Xiao ^b   Hernandez, Adrian F ^c   Levenson, Mark ^b   Li, Ngling ^a   McCloskey, Carolyn ^b   Shoaibi, Azadeh ^b   Wu, Eileen ^b   Zornberg, Gwen ^b   Hennessy, Sean ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; IRBESARTAN; LISINOPRIL; LOSARTAN POTASSIUM; OLMESARTAN; RAMIPRIL; TELMISARTAN; VALSARTAN;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; ANGIOEDEMA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84869102347     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/2013.jamainternmed.34     Document Type: Article

References (42)

1. Chobanian AV, Bakris GL, Black HR, et al Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252. (Pubitemid 37553153)
2. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin- angiotensinaldosterone system. Nat Rev Drug Discov. 2002;1(8):621-636.
3. Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA. 1988;260(7):967-970.
4. Sabroe RA, Black AK. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol. 1997;136(2):153-158. (Pubitemid 27062711)
5. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med. 1992;117(3):234-242.
6. Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitor- induced angioedema: incidence, prevention and management. Drug Saf. 1998; 18(3):171-188. (Pubitemid 28112142)
7. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60(1):8-13. (Pubitemid 26279215)
8. Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008;51(6):1624-1630.
9. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med . 2008; 148(1):16-29. (Pubitemid 351664943)
10. Powers BJ, Coeytaux RR, Dolor RJ, et al. Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information. J Gen Intern Med. 2012;27(6):716-729.
11. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the Sentinel System: a national resource for evidence development. N Engl J Med. 2011;364(6):498-499.
12. Platt R, Carnahan RM, Brown JS, et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012; 21(suppl 1):1-8.
13. Curtis LH, Weiner MG, Boudreau DM, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):23-31.
14. Toh D, Reichman ME, Houstoun M, et al. Protocol for signal refinement of angioedema events in associationwith use of drugs that act on the renin-angiotensinaldosteronesystem. http://www.mini-sentinel.org/work-products/ Assessments/Mini- Sentinel-Angioedema-and-RAAS-Protocol. pdf. Accessed January 17, 2012.
15. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920. (Pubitemid 37323253)
16. Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. JAMA. 1997;278(3):232-233. (Pubitemid 27339590)
17. Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165(14):1637-1642. (Pubitemid 41124159)
18. Mamdani M, Sykora K, Li P, et al. Reader's guide to critical appraisal of cohort studies, 2: assessing potential for confounding. BMJ. 2005;330(7497):960-962. (Pubitemid 40592320)
19. Fireman B, Lee J, Lewis N, Bembom O, van der Laan M, Baxter R. Influenza vaccination and mortality: differentiating vaccine effects from bias. Am J Epidemiol. 2009;170(5):650-656.
20. Fireman B, Toh S, Butler MG, et al. A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):282-290.
21. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
22. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79(387):516- 524.
23. Piller LB, Ford CE, Davis BR, et al ALLHAT Collaborative Research Group. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2006;8(9):649-658.
24. Greaves M, Lawlor F. Angioedema: manifestations and management. J Am Acad Dermatol. 1991;25(1, pt 2):155-165.
25. Gibbs CR, Lip GY, Beevers DG. Angioedema due to ACE inhibitors: increased risk in patients of African origin. Br J Clin Pharmacol. 1999;48(6):861-865.
26. Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10(4):499-509. (Pubitemid 39469033)
27. Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor- associated angioedema. Immunol Allergy Clin North Am. 2006;26(4):725-737. (Pubitemid 44679724)
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-188. (Pubitemid 17189972)
29. Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1. Oxford, England: Cochrane Collaboration; 2008: chap 9.
30. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1920534/?tool=pubmed. Accessed July 31, 2012.
31. Forrow S, Campion DM, Herrinton LJ, et al. The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):12-17.
32. McGraw D, Rosati K, Evans B. A policy framework for public health uses of electronic health data. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):18-22.
33. Pfeffer MA, McMurray JJ, Velazquez EJ, et al Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-1906. (Pubitemid 37409706)
34. Yusuf S, Teo KK, Pogue J, et al ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358 (15):1547-1559. (Pubitemid 351522739)
35. White WB, Bresalier R, Kaplan AP, et al. Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients. J Clin Hypertens (Greenwich). 2011;13(7):506-516.
36. White WB, Bresalier R, Kaplan AP, et al. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J Clin Hypertens (Greenwich). 2010;12(10):765- 775.
37. Toh S, García Rodríguez LA, Hernán MA. Analyzing partially missing confounder information in comparative effectiveness and safety research of therapeutics. Pharmacoepidemiol Drug Saf. 2012;21(suppl 2):13-20.
38. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol . 1995;142(12): 1255-1264. (Pubitemid 26006424)
39. Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
40. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303. (Pubitemid 43797117)
41. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(5):615-625. (Pubitemid 40416916)
42. Toh S, Hernán MA. Causal inference from longitudinal studies with baseline randomization. Int J Biostat. 2008;4(1) Article 22